Members
 | First name: Sylvie Last name: Deuffic-Burban Function: Researcher Position: CR Inserm Email: sylvie.burbaninserm.fr |
Research interest
I am a researcher at Inserm IAME-UMR1137, DeSCID team, and co-leader of the DeSCID team. With a university education in applied mathematics and epidemiology and a PhD in biomathematics, my research themes focus on the modeling of infectious diseases and chronic liver disease, aimed at evaluating the epidemiological, clinical and economic impact of public health interventions. My research projects are particularly focused on hepatitis C (MRC HCVAVERT, https://www.ctu.mrc.ac.uk/studies/all-studies/h/hcvavert/), hepatitis B (H2020 IP -Cure-B, https://ipcureb.eu/principal-investigators/), alcohol-related liver disease, and non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH) (RHU PreciNASH, https://anr.fr/ProjetIA-16-RHUS-0006).
Education
Degree
2014: Habilitation à diriger des recherches
1999: Ph. D. in biomathematics, Paris 6 University
1999: Ph. D. in biomathematics, Paris 6 University
Academic positions
2011-present: Researcher at Inserm (CR1)
Research training (post doctoral)
2019-present: Co-leader of DeSCID team, IAME research unit, Paris
2012-present: Researcher at Inserm, IAME research unit, DeSCID team, Paris
2007-2011: Research fellow at Inserm, U995, Lille
2003-2007: Post-doctoral research fellow at Centre de recherches économiques, sociologiques et de gestion (CRESGE), Lille
2000-2002: Post-doctoral research fellow, Institut Pasteur de Lille, Lille
2012-present: Researcher at Inserm, IAME research unit, DeSCID team, Paris
2007-2011: Research fellow at Inserm, U995, Lille
2003-2007: Post-doctoral research fellow at Centre de recherches économiques, sociologiques et de gestion (CRESGE), Lille
2000-2002: Post-doctoral research fellow, Institut Pasteur de Lille, Lille
List of the main publications
Bauvin P, Delacôte C, Lassailly G, Ntandja Wandji LC, Gnemmi V, Dautrecque F, Louvet A, Caiazzo R, Raverdy V, Leteurtre E, Pattou F, Deuffic-Burban S, Mathurin P
A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients.
Liver International: Official Journal of the International Association for the Study of the Liver 2021, 41, 91-100.
Delacôte C, Bauvin P, Louvet A, Dautrecque F, Ntandja Wandji LC, Lassailly G, Voican C, Perlemuter G, Naveau S, Mathurin P, Deuffic-Burban S
A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression.
Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2020, 18, 2315-2323.e6.
Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, Yazdanpanah Y, Deuffic-Burban S
Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
Gut 2020
Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y
Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Journal of Hepatology 2018, 69, 785-792.
Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, Yazdanpanah Y
Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Journal of Viral Hepatitis 2018, 25, 1197-1207.
Deuffic-Burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P
Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?.
Journal of Hepatology 2017, 66, 304-312.
Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
Hepatology (Baltimore, Md.) 2016, 63, 1090-1101.
Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y
Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Journal of Viral Hepatitis 2016, 23, 767-779.
Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, Attia A, Anwar WA, Cousien A, Tangkijvanich P, Eholié SP, Doss W, Mostafa A, Fontanet A, Mohamed MK, Deuffic-Burban S
How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
Hepatology (Baltimore, Md.) 2015, 62, 31-39.
Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach.
Hepatology (Baltimore, Md.) 2014, 59, 1471-1481.
Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Journal of Hepatology 2014, 61, 7-14.
Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2014, 58, 1064-1071.
Deuffic-Burban S, Castel H, Wiegand J, Manns MP, Wedemeyer H, Mathurin P, Yazdanpanah Y
Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis.
Journal of Hepatology 2012, 57, 260-266.
Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P
Predicted effects of treatment for HCV infection vary among European countries.
Gastroenterology 2012, 143, 974-985.e14.
Deuffic-Burban S, Yazdanpanah Y
It is time to change the paradigm for hepatitis C virus testing.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 54, 1272-1274.
Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos JC, Dhumeaux D, Yazdanpanah Y
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Gut 2012, 61, 290-296.
A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients.
Liver International: Official Journal of the International Association for the Study of the Liver 2021, 41, 91-100.
Delacôte C, Bauvin P, Louvet A, Dautrecque F, Ntandja Wandji LC, Lassailly G, Voican C, Perlemuter G, Naveau S, Mathurin P, Deuffic-Burban S
A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression.
Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2020, 18, 2315-2323.e6.
Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, Yazdanpanah Y, Deuffic-Burban S
Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
Gut 2020
Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y
Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Journal of Hepatology 2018, 69, 785-792.
Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, Yazdanpanah Y
Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Journal of Viral Hepatitis 2018, 25, 1197-1207.
Deuffic-Burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P
Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?.
Journal of Hepatology 2017, 66, 304-312.
Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
Hepatology (Baltimore, Md.) 2016, 63, 1090-1101.
Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y
Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Journal of Viral Hepatitis 2016, 23, 767-779.
Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, Attia A, Anwar WA, Cousien A, Tangkijvanich P, Eholié SP, Doss W, Mostafa A, Fontanet A, Mohamed MK, Deuffic-Burban S
How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
Hepatology (Baltimore, Md.) 2015, 62, 31-39.
Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach.
Hepatology (Baltimore, Md.) 2014, 59, 1471-1481.
Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Journal of Hepatology 2014, 61, 7-14.
Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2014, 58, 1064-1071.
Deuffic-Burban S, Castel H, Wiegand J, Manns MP, Wedemeyer H, Mathurin P, Yazdanpanah Y
Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis.
Journal of Hepatology 2012, 57, 260-266.
Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P
Predicted effects of treatment for HCV infection vary among European countries.
Gastroenterology 2012, 143, 974-985.e14.
Deuffic-Burban S, Yazdanpanah Y
It is time to change the paradigm for hepatitis C virus testing.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 54, 1272-1274.
Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos JC, Dhumeaux D, Yazdanpanah Y
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Gut 2012, 61, 290-296.
Exhaustive list of publications
2022
Castry M, Cousien A, Champenois K, Supervie V, Velter A, Ghosn J, Yazdanpanah Y, Paltiel AD, Deuffic-Burban S
Cost-effectiveness of hepatitis C virus test-and-treat and risk reduction strategies among men who have sex with men living with HIV in France.
Journal of the International AIDS Society 2022, 25, e26035.
2021
Bauvin P, Delacôte C, Lassailly G, Ntandja Wandji LC, Gnemmi V, Dautrecque F, Louvet A, Caiazzo R, Raverdy V, Leteurtre E, Pattou F, Deuffic-Burban S, Mathurin P
A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients.
Liver International: Official Journal of the International Association for the Study of the Liver 2021, 41, 91-100.
Castry M, Cousien A, Bellet J, Champenois K, Pialoux G, Yazdanpanah Y, Costagliola D, Grabar S, Deuffic-Burban S, FHDoH(CFC
Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017.
Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2021, 26,
2020
Delacôte C, Bauvin P, Louvet A, Dautrecque F, Ntandja Wandji LC, Lassailly G, Voican C, Perlemuter G, Naveau S, Mathurin P, Deuffic-Burban S
A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression.
Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2020, 18, 2315-2323.e6.
Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, Papatheodoridis GV, Peck-Radosavljevic M, Razavi H, Reic T, Schatz E, Tozun N, Younossi Z, Manns MP
Securing sustainable funding for viral hepatitis elimination plans.
Liver International: Official Journal of the International Association for the Study of the Liver 2020, 40, 260-270.
Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, Yazdanpanah Y, Deuffic-Burban S
Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
Gut 2020
2019
Cossais S, Schwarzinger M, Pol S, Fontaine H, Larrey D, Pageaux GP, Canva V, Mathurin P, Yazdanpanah Y, Deuffic-Burban S, Fischer F
Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage.
PLOS ONE 2019, 14, e0215596.
Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals.
Journal of Virus Eradication 2019, 5, 60-66.
2018
Costentin CE, Mourad A, Lahmek P, Causse X, Pariente A, Hagège H, Dobrin AS, Becker C, Marks B, Bader R, Condat B, Héluwaert F, Seitz JF, Lesgourgues B, Denis J, Deuffic-Burban S, Rosa I, Decaens T, CSG
Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study.
Cancer 2018, 124, 1964-1972.
Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y
Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Journal of Hepatology 2018, 69, 785-792.
Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, Yazdanpanah Y
Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Journal of Viral Hepatitis 2018, 25, 1197-1207.
2017
Deuffic-Burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P
Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?.
Journal of Hepatology 2017, 66, 304-312.
Ragonnet R, Deuffic-Burban S, Boesecke C, Guiguet M, Lacombe K, Guedj J, Rockstroh JK, Yazdanpanah Y
Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals.
Open Forum Infectious Diseases 2017, 4, ofw235.
2016
Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
Hepatology (Baltimore, Md.) 2016, 63, 1090-1101.
Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y
Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Journal of Viral Hepatitis 2016, 23, 767-779.
Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, Volant J, Dhumeaux D, Yazdanpanah Y, VHTEg
2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV.
Liver International: Official Journal of the International Association for the Study of the Liver 2016, 36, 1442-1449.
2015
Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, Attia A, Anwar WA, Cousien A, Tangkijvanich P, Eholié SP, Doss W, Mostafa A, Fontanet A, Mohamed MK, Deuffic-Burban S
How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
Hepatology (Baltimore, Md.) 2015, 62, 31-39.
Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y
Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.
Journal of Viral Hepatitis 2015, 22, 213-229.
Deuffic-Burban S, Yazdanpanah Y
Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable.
Gut 2015, 64, 1190-1191.
Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
Gut 2015, 64, 1824-1833.
2014
Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach.
Hepatology (Baltimore, Md.) 2014, 59, 1471-1481.
Deuffic-Burban S, Mathurin P, Rosa I, Bouvier AM, Cannesson A, Mourad A, Canva V, Louvet A, Deltenre P, Boleslawski E, Truant S, Pruvot FR, Dharancy S
Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach.
Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2014, 46, 157-163.
Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Journal of Hepatology 2014, 61, 7-14.
Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2014, 58, 1064-1071.
Cousien A, Obach D, Deuffic-Burban S, Mostafa A, Esmat G, Canva V, El Kassas M, El-Sayed M, Anwar WA, Fontanet A, Mohamed MK, Yazdanpanah Y
Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt.
BMC medical research methodology 2014, 14, 39.
2013
Deuffic-Burban S, Yazdanpanah Y
Mathematical modeling: a tool for selecting agents with complementary modes of action?.
Journal of Hepatology 2013, 59, 1346-1348.
Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S, Dominguez A, Donoghoe M, Elzouki AN, Ben-Alaya Bouafif N, Esmat G, Esteban R, Fabri M, Fenton K, Goldberg D, Goulis I, Hadjichristodoulou C, Hadjichristodoulou T, Hatzigeorgiou T, Hamouda O, Hasurdjiev S, Hughes S, Kautz A, Malik M, Manolakopoulos S, Matičič M, Papatheodoridis G, Peck R, Peterle A, Potamitis G, Prati D, Roudot-Thoraval F, Reic T, Sharara A, Shennak M, Shiha G, Shouval D, Sočan M, Thomas H, Thursz M, Tosti M, Trépo C, Vince A, Vounou E, Wiessing L, Manns M
The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference.
Journal of Viral Hepatitis 2013, 20 Suppl 2, 1-20.
Champenois K, Cousien A, Cuzin L, Le Vu S, Deuffic-Burban S, Lanoy E, Lacombe K, Patey O, Béchu P, Calvez M, Semaille C, Yazdanpanah Y
Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study.
BMC infectious diseases 2013, 13, 200.
2012
Deuffic-Burban S, Castel H, Wiegand J, Manns MP, Wedemeyer H, Mathurin P, Yazdanpanah Y
Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis.
Journal of Hepatology 2012, 57, 260-266.
Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P
Predicted effects of treatment for HCV infection vary among European countries.
Gastroenterology 2012, 143, 974-985.e14.
Deuffic-Burban S, Yazdanpanah Y
It is time to change the paradigm for hepatitis C virus testing.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 54, 1272-1274.
Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y
Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.
HIV Med 2012, 13, 148-55.
Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos JC, Dhumeaux D, Yazdanpanah Y
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Gut 2012, 61, 290-296.
Colombie V, Pugliese-Wehrlen S, Deuffic-Burban S, Cuzin L, Pugliese P, Katlama C, Poizot-Martin I, Raffi F, Cabie A, Dellamonica P, Yazdanpanah Y, D
Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription.
International journal of STD & AIDS 2012, 23, 865-869.
